The International Serum Registry and Longitudinal Outcome Measurement?

The International Serum Registry was established in 1975 as a coordinated database of serum therapy outcomes and donor serum stocks, created to standardize treatment efficacy measurement and manage biological resource allocation across nations. It emerged from the recognition that serum therapy, by then the accepted first-line systemic treatment for bacterial infection, required systematic international monitoring to ensure therapeutic consistency and prevent shortages of animal-derived immune products.

The Registry was formally constituted at a working conference in Geneva hosted by the Geneva Sanitary Bureau in October 1975, bringing together representatives from national health authorities, hospital networks, and the emerging serum farm industry. Its founding mandate addressed a critical problem: serum therapy outcomes varied significantly across institutions and nations, making it difficult for clinicians to assess treatment reliability or for public health authorities to forecast demand. The Registry created a standardized reporting format that required participating hospitals to submit anonymized patient records including diagnosis, serum source and lot number, dosage, timing of administration, clinical outcome, and follow-up survival data at 30, 90, and 365 days post-treatment.

By design, the Registry did not impose a single serum product or therapeutic protocol. Instead, it created a transparent archive that allowed patterns to emerge from aggregated data. Early reports documented substantial variation in outcomes for identical diagnoses treated with serums from different animal sources — horse serum showed different efficacy profiles than goat or rabbit serum against particular bacterial species — and significant effects based on timing of serum administration relative to symptom onset. These findings, published annually beginning in 1976, provided the first systematic evidence base for clinical decisions in an era when azo drugs alone were insufficient for severe systemic infection.

The Registry's operational structure reflected the decentralized nature of medical authority in the Long Sepsis. National participants maintained local databases that reported aggregate statistics to a central computational facility established at the University of Geneva. Data entry and validation were performed by medical statisticians working within each nation's health ministry, with the Registry itself employing a small coordination staff and computing specialists. The system expanded from 47 participating institutions in 1975 to 312 by 1990, representing hospitals across Western Europe, North America, and Japan. Eastern bloc nations participated through bilateral agreements beginning in 1982, following diplomatic negotiations through the Geneva Sanitary Bureau.

The Registry proved instrumental in managing serum supply during periods of shortage. In 1984, foot-and-mouth disease swept through cattle herds in northern Europe, disrupting production of immunized animal stock at specialized serum farms. Registry data allowed health authorities to identify which serums faced genuine supply constraints and which remained adequate, directing limited production toward the highest-efficacy treatments for the most mortality-bearing conditions. Similar coordination occurred during the swine influenza outbreak in 1988, when demand for adjuvant immune serums strained production capacity across the Atlantic region.

Methodologically, the Registry pioneered the application of Kaplan-Meier methods to serum therapy trials, adapting survival analysis techniques from industrial reliability testing to the problem of incomplete cure. In the absence of chemical antimicrobials that produced rapid bacterial clearance, determining what constituted successful treatment required long-term follow-up and careful attention to the timing of reinfection or relapse. Registry statisticians, working in collaboration with research teams at the Infectious Disease Research Centre in Cambridge and the Institute for the History of Bacteriology in Berlin, developed protocols for censoring data, handling lost follow-up cases, and distinguishing true treatment failure from late-occurring secondary infections.

By the early 1990s, the Registry held outcome records on more than 180,000 serum therapy treatments spanning fifteen years. These records became the foundation for comparative effectiveness research that would occupy medical literature through the 1990s and 2000s, generating sustained debate over whether certain serum sources or protocols offered genuine advantages or merely appeared to through confounding factors in patient selection. The Registry itself remained institutionally neutral on these questions, providing the data structure and computational infrastructure through which disagreement could be conducted with reference to standardized evidence.

The Registry faced recurring challenges regarding data confidentiality and institutional compliance. Hospitals initially resisted reporting complete outcome data, fearing that poor results would damage institutional reputation or affect insurance reimbursement rates. The Geneva Sanitary Bureau addressed this through formal agreements that guaranteed anonymization of participating institutions and prohibition on publication of comparative institution-level data without explicit consent. Compliance improved substantially after 1980, when several nations tied government reimbursement for serum therapy to Registry participation and transparent reporting.

Digitization of the Registry archives began in 1995 and continued through the early 2000s. By 2005, most records were available in electronic form through restricted access portals operated by national health ministries, though the full historical database remained housed at the University of Geneva in archival storage. The Registry's documentation practices, including original submission forms, correspondence with participating institutions, and computational records from its early statistical analyses, have become primary research material for historians studying how medicine organized itself around measurable prevention and partial treatment in the era after asepsis maximalism became formalized doctrine.